VRCA Begins COVE-3 Trial
Verrica Pharmaceuticals announces the first US patient dosed in the COVE-3 trial for YCANTH to treat common warts
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Verrica Pharmaceuticals announces the first US patient dosed in the COVE-3 trial for YCANTH to treat common warts